Search results
Results from the WOW.Com Content Network
Lobular carcinoma in situ (LCIS) is an incidental microscopic finding with characteristic cellular morphology and multifocal tissue patterns. The condition is a laboratory diagnosis and refers to unusual cells in the lobules of the breast . [ 1 ]
Histopathologic types of breast cancer, with relative incidences and prognoses, with "invasive lobular carcinoma" at top right. Invasive lobular carcinoma (ILC) is breast cancer arising from the lobules of the mammary glands. [1]
Tissue samples will be looked at under the microscope for histopathological type, grade, and stage. Immunohistochemical staining is used to establish receptor status, and the presence or absence of pertinent genes is determined by DNA testing. This article will discuss the features specific to invasive carcinoma NST.
An admission note is part of a medical record that documents the patient's status (including history and physical examination findings), reasons why the patient is being admitted for inpatient care to a hospital or other facility, and the initial instructions for that patient's care.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Ductal carcinoma in situ (DCIS) breast cancer [ edit ] "DCIS patients and control subjects did not differ with respect to oral contraceptive use, hormone replacement therapy, alcohol consumption or smoking history, or breast self-examination.
Carcinoma in situ (CIS) is a group of abnormal cells. [ 1 ] [ 2 ] While they are a form of neoplasm , [ 3 ] there is disagreement over whether CIS should be classified as cancer . This controversy also depends on the exact CIS in question (e.g., cervical, skin, breast).
Chromogenic in situ hybridization (CISH) is a cytogenetic technique that combines the chromogenic signal detection method of immunohistochemistry (IHC) techniques with in situ hybridization. [ 1 ] [ 2 ] It was developed around the year 2000 as an alternative to fluorescence in situ hybridization (FISH) for detection of HER-2/neu oncogene ...